N. Suzuki

发表

Synthesis, structure-activity relationship, and pharmacological studies of novel melanin-concentrating hormone receptor 1 antagonists 3-aminomethylquinolines: reducing human ether-a-go-go-related gene (hERG) associated liabilities.

J. Kunitomo, Masaharu Nakayama, Koki Kato, 2012, Journal of medicinal chemistry.

T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist.

Yuji Ishihara, Masahiko Fujino, Osamu Nishimura, 2002, European journal of pharmacology.

Melanin-concentrating hormone receptor 1 antagonists. Synthesis and structure-activity relationships of novel 3-(aminomethyl)quinolines.

Koki Kato, Y. Nakano, Toshio Tanaka, 2012, Journal of medicinal chemistry.

Endothelin in myocardial infarction

M. Fujino, N. Suzuki, Toshifumi Watanabe, 1990, Nature.

Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125.

J. Yano, K. Aertgeerts, K. Takeuchi, 2011, Bioorganic & medicinal chemistry.

Regional distribution of pituitary adenylate cyclase activating polypeptide (PACAP) in the rat central nervous system as determined by sandwich-enzyme immunoassay

H. Matsumoto, M. Fujino, Yoshio Matsumoto, 1993, Brain Research.

Plasma endothelin-1 concentrations in the coronary sinus in dogs with artificially induced myocardial infarction

T. Masaki, Y. Sugishita, I. Yamaguchi, 1992, Peptides.

Monoclonal antibodies to human interferon-γ-II: antibodies with neutralizing activity

C. Kitada, N. Suzuki, Y. Ichimori, 1987 .

Design of potent dipeptidyl peptidase IV (DPP-4) inhibitors by employing a strategy to form a salt bridge with Lys554.

M. Tawada, N. Suzuki, S. Tsubotani, 2017, Bioorganic & medicinal chemistry letters.

Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist.

Masahiro Ito, Toshimasa Tanaka, S. Mikami, 2010, ACS medicinal chemistry letters.

Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.

Masahiro Ito, S. Mikami, K. Takeuchi, 2012, Journal of medicinal chemistry.

Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.

M. Sasaki, J. Yano, K. Aertgeerts, 2011, Bioorganic & medicinal chemistry.

Cerebrospinal fluid endothelin-1 in Alzheimer's disease and senile dementia of Alzheimer type

I. Kanazawa, H. Mizusawa, H. Matsumoto, 1992, Neuropeptides.

Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists.

Masahiro Ito, Toshimasa Tanaka, K. Takeuchi, 2012, Journal of medicinal chemistry.

Production of recombinant human relaxin 3 in AtT20 cells

O. Nishimura, S. Hinuma, H. Onda, 2003, Regulatory Peptides.

A new class of potent nonpeptide luteinizing hormone-releasing hormone (LHRH) antagonists: design and synthesis of 2-phenylimidazo[1,2-a]pyrimidin-5-ones.

Masataka Harada, Masahiko Fujino, Shuichi Furuya, 2002, Bioorganic & medicinal chemistry letters.

A New Class of Potent Nonpeptide Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists: Design and Synthesis of 2-Phenylimidazo[1,2-a]pyrimidin-5-one.

S. Sasaki, M. Fujino, M. Harada, 2002 .

Design, synthesis, and structure-activity relationships of thieno[2,3-b]pyridin-4-one derivatives as a novel class of potent, orally active, non-peptide luteinizing hormone-releasing hormone receptor antagonists.

S. Sasaki, T. Imada, H. Matsumoto, 2006, Journal of medicinal chemistry.

Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor.

S. Sasaki, T. Imada, H. Matsumoto, 1998, Journal of medicinal chemistry.

Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor.

Masataka Harada, Masahiko Fujino, Shuichi Furuya, 2003, Journal of medicinal chemistry.

Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.

J. Yano, K. Aertgeerts, K. Takeuchi, 2011, Bioorganic & medicinal chemistry.

Discovery of a 3-pyridylacetic acid derivative (TAK-100) as a potent, selective and orally active dipeptidyl peptidase IV (DPP-4) inhibitor.

J. Yano, K. Aertgeerts, K. Takeuchi, 2011, Journal of medicinal chemistry.

Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes.

Toshimasa Tanaka, S. Mikami, Masami Suzuki, 2012, Journal of medicinal chemistry.

Melanin-concentrating hormone receptor 1 antagonists: synthesis, structure-activity relationship, docking studies, and biological evaluation of 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives.

Koki Kato, Y. Nakano, M. Tawada, 2011, Bioorganic & medicinal chemistry.

Discovery, synthesis, and structure-activity relationship of 6-aminomethyl-7,8-dihydronaphthalenes as human melanin-concentrating hormone receptor 1 antagonists.

Koki Kato, Y. Nakano, S. Endo, 2011, Bioorganic & Medicinal Chemistry.

Cell immunoblot assay study demonstrating the release of PACAP from individual anterior pituitary cells of rats and the effect of PACAP on LH release

A. Arimura, K. Köves, N. Suzuki, 2002, Regulatory Peptides.

A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.

K. Takeuchi, Y. Moritoh, N. Suzuki, 2009, Life sciences.

Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain.

Nobuyuki Miyajima, Masahiko Fujino, C. Kitada, 2003, Biochemical and biophysical research communications.

Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys.

M. Fujino, M. Harada, N. Cho, 2003, The Journal of clinical endocrinology and metabolism.

Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.

Toshimasa Tanaka, Masami Suzuki, M. Harada, 2011, Journal of medicinal chemistry.

Endothelin family peptides in human plasma and urine: Their molecular forms and concentrations

H. Matsumoto, C. Kitada, M. Fujino, 1994, Peptides.

Melanin-concentrating hormone receptor 1 antagonists: synthesis, structure-activity relationship, docking studies, and biological evaluation of 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives.

Koki Kato, Y. Nakano, M. Tawada, 2011, Bioorganic & Medicinal Chemistry.

Day-night variation of pituitary adenylate cyclase-activating polypeptide (PACAP) level in the rat suprachiasmatic nucleus

G. Tsujimoto, Y. Nakayama, C. Fukuhara, 1997, Neuroscience Letters.

Pituitary adenylate cyclase activating polypeptide provokes cultured rat chromaffin cells to secrete adrenaline.

T. Watanabe, H. Matsumoto, C. Kitada, 1992, Biochemical and biophysical research communications.

Corrigendum to “Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554” [Bioorg. Med. Chem. 19 (2011) 4482–4498]

J. Yano, K. Aertgeerts, K. Takeuchi, 2011 .

Discovery of a 3-pyridylacetic acid derivative (TAK-100) as a potent, selective and orally active dipeptidyl peptidase IV (DPP-4) inhibitor.

J. Yano, K. Aertgeerts, K. Takeuchi, 2011, Journal of medicinal chemistry.